Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VVD-133214 · 1 trial · 1 indication
Defined as the proportion of participants who are alive and free from disease progression as per RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| VVD-133214 Dose 1 + Pembrolizumab | EXPERIMENTAL | Participants will receive VVD-133214 in combination with pembrolizumab |
| VVD-133214 Dose 2 + Pembrolizumab | EXPERIMENTAL | Participants will receive VVD-133214 in combination with pembrolizumab |
| Pembrolizumab | ACTIVE_COMPARATOR | Participants will receive pembrolizumab only (monotherapy) |
| Name | Type | Description |
|---|---|---|
| VVD-133214 | DRUG | VVD-133214 will be administered orally |
| Pembrolizumab | DRUG | Pembrolizumab will be administered by intravenous infusion (IV) every three weeks |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 * Have a known microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) tumor status confirmed per local standard of care (SoC), and have histologically or cytologically documented adv...
VVD-133214 is an investigational small molecule being studied for colorectal adenocarcinoma, a type of cancer of the colon or rectum. It is being developed for patients with advanced disease and is evaluated in combination with pembrolizumab. It is not yet approved for any use and remains in clinical development.
VVD-133214 is in Phase 2 clinical development. The single registered trial, NCT07811193, is a Phase 2 study and is currently listed as not yet recruiting. No Phase 3 trial has been registered, and the drug has not completed any trials to date.
VVD-133214 is being developed by Bayer AG, which trades under the ticker BAYRY. Bayer is the sponsor of the Phase 2 study evaluating the drug in colorectal adenocarcinoma. The program is in the oncology therapeutic area.
VVD-133214 is being studied in one registered trial, NCT07811193, titled a study to evaluate the efficacy of VVD-133214 in combination with pembrolizumab compared with pembrolizumab alone in participants with advanced cancer of the colon or rectum. The Phase 2 trial plans to enroll 140 participants across the United States, Europe, Asia, and Latin America.
VVD-133214 is not approved. It is an investigational small molecule still in clinical development, currently in Phase 2 testing for colorectal adenocarcinoma. The only registered study, NCT07811193, has not yet begun recruiting, so the drug remains under investigation and is not available as an approved therapy.
NCT07811193 is a randomized, active-controlled Phase 2 trial comparing VVD-133214 plus pembrolizumab against pembrolizumab alone in adults with advanced colorectal adenocarcinoma. It is not double blinded, plans to enroll 140 participants, and includes biomarker-selected patients. Participants must be 18 years or older, and the study is not yet recruiting.